<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889859</url>
  </required_header>
  <id_info>
    <org_study_id>KNUCH 2019-04-004</org_study_id>
    <nct_id>NCT04889859</nct_id>
  </id_info>
  <brief_title>Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy</brief_title>
  <official_title>Impact of the Length of Biliopancreatic Limb on Diabetes Associated With the Changes in Incretin Hormone and Gut Microbiota Following Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University Chilgok Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyungpook National University Chilgok Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized controlled trial to investigate the impact of a long&#xD;
      biliopancreatic limb of Roux-en-Y reconstruction on diabetes control in patients with&#xD;
      concurrent type 2 diabetes and gastric cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study aimed to compare the changes in glucose metabolism and incretin hormone&#xD;
      responses following long-limb bypass Roux-en-Y reconstruction with different biliopancreatic&#xD;
      limb lengths after distal gastrectomy in gastric cancer patients with type 2 diabetes. This&#xD;
      is a prospective, single-center, randomized controlled trial. Patients diagnosed with stage I&#xD;
      gastric cancer and type 2 diabetes are eligible for the present study. Patients who will&#xD;
      undergo laparoscopic distal gastrectomy for cancer located at the lower two-thirds of the&#xD;
      stomach will only be included.&#xD;
&#xD;
      The reconstruction method will be randomly assigned among long-Roux limb Roux-en-Y (with 100&#xD;
      cm-long Roux limb &amp; 50cm-long biliopancreatic limb) or long-biliopancreatic limb Roux-en-Y&#xD;
      (with 50 cm-long Roux limb &amp; 100cm-long biliopancreatic limb) reconstruction methods.&#xD;
&#xD;
      All the patients are subjected to a 75g-oral glucose tolerance test (OGTT) preoperatively,&#xD;
      and at 3 months, 6 months postoperatively, and serum glucose, as well as incretin hormones,&#xD;
      will be serially measured. Fecal samples will be obtained preoperatively and at 3 months&#xD;
      after surgery for gut microbiota analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diabetes remission rate (%)</measure>
    <time_frame>6 months</time_frame>
    <description>rate of the patients with HbA1c &lt; 6.5% without medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>delta HbA1c (%)</measure>
    <time_frame>6 months</time_frame>
    <description>difference of preoperative HbA1c and postoperative HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in body mass index (BMI, kg/m2)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>difference of preoperative BMI and postoperative BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in body fat mass (kg)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>difference in body fat mass measured by bioimpedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in lean body mass (kg)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>difference in lean body mass measured by bioimpedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in blood glucose and insulin concentration</measure>
    <time_frame>up to 6 months</time_frame>
    <description>changes in dynamic blood glucose and insulin levels up to 2 hours after 75g - oral glucose challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in dynamic incretin hormone secretion</measure>
    <time_frame>up to 6 months</time_frame>
    <description>changes in dynamic GLP-1 and GIP secretion up to 2 hours after 75g oral glucose challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in gut microbiota</measure>
    <time_frame>before &amp; at 3 months after surgery</time_frame>
    <description>gut microbiota analysis from the fecal samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stomach Neoplasm</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>long RL group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>long Roux limb Roux-en-Y reconstruction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>long BPL group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>long biliopancreatic limb Roux-en-Y reconstruction</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>long Roux limb Roux-en-Y reconstruction</intervention_name>
    <description>After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and 50 cm-long biliopancreatic limb.</description>
    <arm_group_label>long RL group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>long biliopancreatic limb Roux-en-Y reconstruction</intervention_name>
    <description>After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 50 cm-long Roux limb and 100 cm-long biliopancreatic limb.</description>
    <arm_group_label>long BPL group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with type 2 diabetes as well as pathologically proven gastric&#xD;
             cancer of clinical stage I according to the AJCC 8th edition&#xD;
&#xD;
          -  Those who are expected to undergo laparoscopic distal gastrectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. baseline fasting C-peptide level &lt; 1.0 ng/dL (who had the possibility of type 1&#xD;
             diabetes)&#xD;
&#xD;
          2. previous radiotherapy or surgery at upper abdomen other than laparoscopic&#xD;
             cholecystectomy&#xD;
&#xD;
          3. other malignancies in recent 5 years&#xD;
&#xD;
          4. vulnerable patients (pregnant women, those with cognitive impairment, etc)&#xD;
&#xD;
          5. ECOG-PS â‰¥ 2&#xD;
&#xD;
          6. participating in other clinical trials within 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Yeon Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Chilgok Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Yeon Park, MD</last_name>
    <phone>+82-53-200-2714</phone>
    <email>jybark99@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>JI YEON</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JI YEON Park, MD</last_name>
      <phone>+82-53-200-2714</phone>
      <email>jybark99@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Ji Yeon Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>incretin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

